<DOC>
	<DOC>NCT00248170</DOC>
	<brief_summary>Eligible patients will be post-menopausal hormone receptor- and lymph node-positive females who recently underwent primary surgery for breast cancer. Patients will be randomized to letrozole (2.5 mg per day for 5 years) vs anastrozole (1 mg per day for 5 years). Follow up will occur for 5 years after the completion of enrollment for survival and disease status updates.</brief_summary>
	<brief_title>Comparison Trial of Letrozole to Anastrozole in the Adjuvant Treatment of Postmenopausal Women With Hormone Receptor and Node Positive Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Anastrozole</mesh_term>
	<mesh_term>Letrozole</mesh_term>
	<criteria>Recent primary surgery for breast cancer Early stage breast cancer Postmenopausal Hormone receptor positive Positive lymph node involvement Metastatic disease Presence of contralateral breast cancer including DCIS Progression Other protocoldefined inclusion/exclusion criteria may apply.</criteria>
	<gender>Female</gender>
	<minimum_age>33 Years</minimum_age>
	<maximum_age>96 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Breast cancer</keyword>
	<keyword>letrozole</keyword>
	<keyword>anastrozole</keyword>
	<keyword>adjuvant</keyword>
	<keyword>postmenopausal</keyword>
	<keyword>FACE</keyword>
</DOC>